Association of metabolic complication with plasma mid-regional pro adrenomedullin level in stable kidney transplant recipients
Association of metabolic complication with plasma mid-regional pro adrenomedullin level in stable kidney transplant recipients
复制标题
稳定肾移植受者代谢并发症与血浆中区肾上腺髓质素原水平的关联
DOI：
10.1016/j.cca.2015.12.016
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Itoh H
中科院分区：
文献类型：
--
作者：
Suzuki Y;Katagiri F;Sato F;Fujioka T;Tanaka R;Sato Y;Mimata H;Itoh H
背景近年来，慢性肾功能衰竭患者血浆肾上腺髓质素原（pro-adrenomedullin，MR-proADM）浓度升高。在这项研究中，我们试图确定重要的临床因素与MR-proADM浓度在稳定的肾移植recipients. MethodsForty七个日本肾移植受者进行移植> 180天前的研究进行了分析。为了便于接受不同药物的接受者之间的抗高血压方案的可比性，我们计算了每个接受者的抗高血压药物治疗强度评分。早晨血液样本收集和血浆MR-proADM浓度测定使用酶immunoassociation.ResultsMultiple回归分析确定治疗强度评分为抗高血压药物，血清白蛋白，肌酐清除率和使用降脂药物作为显着的独立因素与血浆MR-proADM浓度。校正后的决定系数为0.46。结论稳定期肾移植患者血浆MR-proADM浓度除提示肾功能下降外，还可作为代谢紊乱，尤其是高血压和高脂血症的一个有用的生物标志物。
BackgroundRecently, increased plasma mid-regional pro-adrenomedullin (MR-proADM) concentrations have been demonstrated in patients with chronic renal failure. In this study, we attempted to identify significant clinical factors associated with MR-proADM concentration in stable kidney transplant recipients.MethodsForty-seven Japanese kidney transplant recipients who underwent transplantation > 180 days prior to the study were analyzed. To facilitate comparability of anti-hypertensive regimens across recipients taking different drugs, we calculated the treatment intensity score of anti-hypertensive drugs in each recipient. Morning blood samples were collected and plasma MR-proADM concentrations were measured using an enzyme immunoassay.ResultsMultiple regression analysis identified treatment intensity score for anti-hypertensive drugs, serum albumin, creatinine clearance and use of lipid-lowering agents as significant independent factors associated with plasma MR-proADM concentration. Adjusted coefficient of determination for this model was 0.46.ConclusionApart from indicating lowered renal function, plasma MR-proADM concentration may be a useful biomarker for metabolic disorders, especially hypertension and hyperlipidemia, in stable kidney transplant patients.